HC Wainwright Forecasts Higher Earnings for Rockwell Medical

Rockwell Medical, Inc. (NASDAQ:RMTI) – Analysts at HC Wainwright lifted their Q4 2026 earnings per share (EPS) estimates for Rockwell Medical in a note issued to investors on Monday, January 26th. HC Wainwright analyst R. Selvaraju now expects that the company will earn $0.01 per share for the quarter, up from their previous estimate of ($0.01). HC Wainwright currently has a “Buy” rating and a $2.50 target price on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is $0.03 per share.

RMTI has been the topic of several other research reports. Wall Street Zen lowered Rockwell Medical from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rockwell Medical in a research note on Thursday. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $2.50.

Rockwell Medical Stock Down 5.2%

NASDAQ RMTI opened at $1.09 on Tuesday. Rockwell Medical has a twelve month low of $0.78 and a twelve month high of $2.19. The stock has a market cap of $42.95 million, a PE ratio of -6.81 and a beta of 1.65. The firm has a 50-day simple moving average of $0.93 and a 200 day simple moving average of $1.11. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.50 and a current ratio of 3.91.

Institutional Investors Weigh In On Rockwell Medical

Several large investors have recently made changes to their positions in the company. Panagora Asset Management Inc. bought a new position in Rockwell Medical during the 2nd quarter valued at about $41,000. GSA Capital Partners LLP raised its stake in shares of Rockwell Medical by 635.1% in the third quarter. GSA Capital Partners LLP now owns 163,978 shares of the company’s stock valued at $197,000 after acquiring an additional 141,672 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Rockwell Medical by 12.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,354,147 shares of the company’s stock worth $1,625,000 after acquiring an additional 148,737 shares in the last quarter. Institutional investors own 23.31% of the company’s stock.

Rockwell Medical Company Profile

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.